Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.

Foka P, Dimitriadis A, Karamichali E, Kyratzopoulou E, Giannimaras D, Koskinas J, Varaklioti A, Mamalaki A, Georgopoulou U.

Virulence. 2016 Aug 17;7(6):679-90. doi: 10.1080/21505594.2016.1175700. Epub 2016 Apr 8.

2.

Low Serum Hepcidin in Patients with Autoimmune Liver Diseases.

Lyberopoulou A, Chachami G, Gatselis NK, Kyratzopoulou E, Saitis A, Gabeta S, Eliades P, Paraskeva E, Zachou K, Koukoulis GK, Mamalaki A, Dalekos GN, Simos G.

PLoS One. 2015 Aug 13;10(8):e0135486. doi: 10.1371/journal.pone.0135486. eCollection 2015.

3.

Rapid elevation of transferrin saturation and serum hepcidin concentration in hemodialysis patients after intravenous iron infusion.

Kitsati N, Liakos D, Ermeidi E, Mantzaris MD, Vasakos S, Kyratzopoulou E, Eliadis P, Andrikos E, Kokkolou E, Sferopoulos G, Mamalaki A, Siamopoulos K, Galaris D.

Haematologica. 2015 Mar;100(3):e80-3. doi: 10.3324/haematol.2014.116806. Epub 2014 Nov 25. No abstract available.

4.

A complex signaling network involving protein kinase CK2 is required for hepatitis C virus core protein-mediated modulation of the iron-regulatory hepcidin gene expression.

Foka P, Dimitriadis A, Kyratzopoulou E, Giannimaras DA, Sarno S, Simos G, Georgopoulou U, Mamalaki A.

Cell Mol Life Sci. 2014 Nov;71(21):4243-58. doi: 10.1007/s00018-014-1621-4. Epub 2014 Apr 10.

PMID:
24718935
5.

Hepcidin and the iron enigma in HCV infection.

Georgopoulou U, Dimitriadis A, Foka P, Karamichali E, Mamalaki A.

Virulence. 2014 May 15;5(4):465-76. doi: 10.4161/viru.28508. Epub 2014 Mar 13. Review.

6.

The glycosylated IgII extracellular domain of EMMPRIN is implicated in the induction of MMP-2.

Papadimitropoulou A, Mamalaki A.

Mol Cell Biochem. 2013 Jul;379(1-2):107-13. doi: 10.1007/s11010-013-1632-8. Epub 2013 Apr 6.

PMID:
23716178
7.

Connection between telomerase activity in PBMC and markers of inflammation and endothelial dysfunction in patients with metabolic syndrome.

Rentoukas E, Tsarouhas K, Kaplanis I, Korou E, Nikolaou M, Marathonitis G, Kokkinou S, Haliassos A, Mamalaki A, Kouretas D, Tsitsimpikou C.

PLoS One. 2012;7(4):e35739. doi: 10.1371/journal.pone.0035739. Epub 2012 Apr 25.

8.

The 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimer.

Sidera K, El Hamidieh A, Mamalaki A, Patsavoudi E.

PLoS One. 2011;6(9):e23906. doi: 10.1371/journal.pone.0023906. Epub 2011 Sep 1.

9.

Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques.

Lioupis C, Barbatis C, Drougou A, Koliaraki V, Mamalaki A, Klonaris C, Georgopoulos S, Andrikopoulos V, Bastounis E.

Atherosclerosis. 2011 May;216(1):131-8. doi: 10.1016/j.atherosclerosis.2011.01.028. Epub 2011 Jan 26.

PMID:
21316675
10.

A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.

Gattenlöhner S, Jörissen H, Huhn M, Vincent A, Beeson D, Tzartos S, Mamalaki A, Etschmann B, Muller-Hermelink HK, Koscielniak E, Barth S, Marx A.

J Biomed Biotechnol. 2010;2010:187621. doi: 10.1155/2010/187621. Epub 2010 Feb 24.

11.

Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C.

Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ.

J Viral Hepat. 2010 Nov;17(11):800-6. doi: 10.1111/j.1365-2893.2009.01244.x.

PMID:
20002304
12.

Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization.

Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW.

Haematologica. 2009 Dec;94(12):1748-52. doi: 10.3324/haematol.2009.010322.

13.

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.

Lekka E, Gritzapis AD, Perez SA, Tsavaris N, Missitzis I, Mamalaki A, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2010 May;59(5):715-27. doi: 10.1007/s00262-009-0791-7. Epub 2009 Nov 11.

PMID:
19904532
14.

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.

Dimitriadis A, Gontinou C, Baxevanis CN, Mamalaki A.

BMC Cancer. 2009 Oct 30;9:386. doi: 10.1186/1471-2407-9-386.

15.

A novel immunological assay for hepcidin quantification in human serum.

Koliaraki V, Marinou M, Vassilakopoulos TP, Vavourakis E, Tsochatzis E, Pangalis GA, Papatheodoridis G, Stamoulakatou A, Swinkels DW, Papanikolaou G, Mamalaki A.

PLoS One. 2009;4(2):e4581. doi: 10.1371/journal.pone.0004581. Epub 2009 Feb 24.

16.

Iron regulatory and bactericidal properties of human recombinant hepcidin expressed in Pichia pastoris.

Koliaraki V, Marinou M, Samiotaki M, Panayotou G, Pantopoulos K, Mamalaki A.

Biochimie. 2008 May;90(5):726-35. doi: 10.1016/j.biochi.2008.01.012. Epub 2008 Feb 6.

PMID:
18295606
17.

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.

Belimezi MM, Papanastassiou D, Merkouri E, Baxevanis CN, Mamalaki A.

Cancer Immunol Immunother. 2006 Sep;55(9):1091-9. Epub 2005 Nov 26.

PMID:
16311733
18.

Characterization of the BM88 promoter and identification of an 88 bp fragment sufficient to drive neurone-specific expression.

Papadodima O, Sergaki M, Hurel C, Mamalaki A, Matsas R.

J Neurochem. 2005 Oct;95(1):146-59.

19.
23.

Future therapeutic strategies in autoimmune myasthenia gravis.

Psaridi-Linardaki L, Mamalaki A, Tzartos SJ.

Ann N Y Acad Sci. 2003 Sep;998:539-48.

PMID:
14592926
24.

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.

Mamalaki A, Gritzapis AD, Kretsovali A, Belimezi M, Papamatheakis J, Perez SA, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Aug;52(8):513-22. Epub 2003 Apr 25.

PMID:
12715240
25.

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Gritzapis AD, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez SA, Baxevanis CN, Papamichail M.

Br J Cancer. 2003 Apr 22;88(8):1292-300.

26.
27.

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.

Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2002 Jan;50(11):615-24. Epub 2001 Nov 23.

PMID:
11807625
28.

Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.

Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M.

Br J Cancer. 2001 Nov 16;85(10):1527-34.

29.

Cloning, expression and localization of human BM88 shows that it maps to chromosome 11p15.5, a region implicated in Beckwith-Wiedemann syndrome and tumorigenesis.

Gaitanou M, Buanne P, Pappa C, Georgopoulou N, Mamalaki A, Tirone F, Matsas R.

Biochem J. 2001 May 1;355(Pt 3):715-24.

30.

Isolation of a mouse brain cDNA expressed in developing neuroblasts and mature neurons.

Boutou E, Matsas R, Mamalaki A.

Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):153-67.

PMID:
11165382
32.

The crystal structure of the Fab fragment of a rat monoclonal antibody against the main immunogenic region of the human muscle acetylcholine receptor.

Kontou M, Leonidas DD, Vatzaki EH, Tsantili P, Mamalaki A, Oikonomakos NG, Acharya KR, Tzartos SJ.

Eur J Biochem. 2000 Apr;267(8):2389-97.

33.

The third-dimensional structure of the complex between an Fv antibody fragment and an analogue of the main immunogenic region of the acetylcholine receptor: a combined two-dimensional NMR, homology, and molecular modeling approach.

Kleinjung J, Petit MC, Orlewski P, Mamalaki A, Tzartos SJ, Tsikaris V, Sakarellos-Daitsiotis M, Sakarellos C, Marraud M, Cung MT.

Biopolymers. 2000 Feb;53(2):113-28.

PMID:
10679615
34.

Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease.

Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK.

J Neurochem. 1999 Oct;73(4):1635-40.

35.

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.

Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A, Papamichail M.

Cancer Immunol Immunother. 1999 May-Jun;48(2-3):71-84.

PMID:
10414460
36.

Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor.

Papanastasiou D, Mamalaki A, Eliopoulos E, Poulas K, Liolitsas C, Tzartos SJ.

J Neuroimmunol. 1999 Feb 1;94(1-2):182-95.

PMID:
10376952
37.

High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor.

Tsantili P, Tzartos SJ, Mamalaki A.

J Neuroimmunol. 1999 Feb 1;94(1-2):15-27.

PMID:
10376932
38.

Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor.

Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P, Tsikaris V.

Immunol Rev. 1998 Jun;163:89-120. Review.

PMID:
9700504
39.

Construction of single-chain Fv fragments of anti-MIR monoclonal antibodies.

Tzartos SJ, Tsantili P, Papanastasiou D, Mamalaki A.

Ann N Y Acad Sci. 1998 May 13;841:475-7. No abstract available.

PMID:
9668278
40.

Overexpression of the neuron-specific molecule BM88 in mouse neuroblastoma cells: altered responsiveness to growth factors.

Gomez J, Boutou E, Hurel C, Mamalaki A, Kentroti S, Vernadakis A, Matsas R.

J Neurosci Res. 1998 Jan 1;51(1):119-28.

PMID:
9452316
41.

Purification and cDNA cloning of mouse BM89 antigen shows that it is identical with the synaptic vesicle protein synaptophysin.

Gaitanou M, Mamalaki A, Merkouri E, Matsas R.

J Neurosci Res. 1997 Jun 15;48(6):507-14.

PMID:
9210520
42.

Antigenic structure of the muscle nicotinic acetylcholine receptor.

Tzartos SJ, Cung MT, Mamalaki A, Marraud M, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P.

Ann Med Interne (Paris). 1996;147(6):442-6. Review. No abstract available.

PMID:
9092347
43.

The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells.

Mamalaki A, Boutou E, Hurel C, Patsavoudi E, Tzartos S, Matsas R.

J Biol Chem. 1995 Jun 9;270(23):14201-8.

44.
45.

Expression of the major surface glycoprotein of Leishmania, gp63, in wild-type and sinefungin-resistant promastigotes.

Soteriadou KP, Tzinia AK, Mamalaki A, Phelouzat MA, Lawrence F, Robert-Gero M.

Eur J Biochem. 1994 Jul 1;223(1):61-8.

46.

Nicotinic acetylcholine receptor: structure, function and main immunogenic region.

Mamalaki A, Tzartos SJ.

Adv Neuroimmunol. 1994;4(4):339-54. Review. No abstract available.

PMID:
7719615
48.

The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Tzartos SJ, Cung MT, Demange P, Loutrari H, Mamalaki A, Marraud M, Papadouli I, Sakarellos C, Tsikaris V.

Mol Neurobiol. 1991 Spring;5(1):1-29. Review.

PMID:
1725702
49.
50.

Supplemental Content

Loading ...
Support Center